Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles
- PMID: 21882017
- PMCID: PMC3241835
- DOI: 10.1007/s10815-011-9627-4
Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles
Abstract
Objective: To evaluate predictive role of day-3 serum anti-Müllerian hormone (AMH) levels and antral follicle count (AFC) in ovarian hyperstimulation syndrome (OHSS) in patients undergoing IVF/ICSI cycles.
Materials and methods: Forty-one women with moderate/severe OHSS and 41 age matched women without OHSS were compared to evaluate the predictive value of certain risk factors for OHSS. AFC, and E(2), FSH, LH, AMH, inhibin-B levels measured on day 3 of the menstrual cycle before controlled ovarian hyperstimulation.
Results: Mean FSH was significantly lower (p < 0.0001); and mean LH, AFC and AMH were significantly higher in women with OHSS compared to women without OHSS (p = 0.049, p < 0.0001 and p < 0.0001, respectively). There was no significant difference in inhibin B (p = 0.112) and estradiol (p = 0.706) between the groups. The ROC area under curve (AUC) for AMH presented the largest AUC among the listed risk factors. AMH (AUC = 0.87) and AFC (AUC = 0.74) had moderate accuracy for predicting OHSS while Inhibin B (AUC = 0.58) and LH (AUC = 0.61) had low accuracy. The cut-off value for AMH 3.3 ng/mL provided the highest sensitivity (90%) and specificity (71%) for predicting OHSS. It's positive (PPV) and negative predictive values (NPV) were 61% and 94%, respectively. The cut-off value for AFC was 8 with 78% sensitivity, 65% specificity, 52% PPV and 86% NPV.
Conclusion: Measurement of basal serum AMH and AFC can be used to determine the women with high risk for OHSS.
Figures
Similar articles
-
Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.Fertil Steril. 2009 Nov;92(5):1586-93. doi: 10.1016/j.fertnstert.2008.08.127. Epub 2008 Oct 18. Fertil Steril. 2009. PMID: 18930213 Clinical Trial.
-
Interactions between serum FSH, inhibin B and antral follicle count in the decline of serum AMH during the menstrual cycle in late reproductive age.Endocrinol Diabetes Metab. 2020 Aug 8;4(2):e00172. doi: 10.1002/edm2.172. eCollection 2021 Apr. Endocrinol Diabetes Metab. 2020. PMID: 33855196 Free PMC article.
-
Anti-Mullerian hormone is a better marker than inhibin B, follicle stimulating hormone, estradiol or antral follicle count in predicting the outcome of in vitro fertilization.Arch Gynecol Obstet. 2011 Jun;283(6):1415-21. doi: 10.1007/s00404-011-1889-7. Epub 2011 Mar 29. Arch Gynecol Obstet. 2011. PMID: 21562964
-
Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction.Reprod Biomed Online. 2014 Feb;28(2):183-90. doi: 10.1016/j.rbmo.2013.10.012. Epub 2013 Oct 25. Reprod Biomed Online. 2014. PMID: 24368127 Review.
-
Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response.Hum Reprod Update. 2015 Nov-Dec;21(6):698-710. doi: 10.1093/humupd/dmu062. Epub 2014 Dec 8. Hum Reprod Update. 2015. PMID: 25489055 Review.
Cited by
-
Antral follicle count and anti-Müllerian hormone level as predictors of ovarian hyperstimulation syndrome in women with polycystic ovarian syndrome undergoing controlled ovarian stimulation.J Ultrason. 2021 Aug 16;21(86):e200-e205. doi: 10.15557/JoU.2021.0032. Epub 2021 Sep 9. J Ultrason. 2021. PMID: 34540273 Free PMC article.
-
Attenuated AMH signaling pathway plays an important role in the pathogenesis of ovarian hyperstimulation syndrome.Am J Transl Res. 2015 Oct 15;7(10):1925-38. eCollection 2015. Am J Transl Res. 2015. PMID: 26692936 Free PMC article.
-
Risk Factors and Methods for Predicting Ovarian Hyperstimulation Syndrome (OHSS) in the in vitro Fertilization.Arch Razi Inst. 2021 Nov 30;76(5):1461-1468. doi: 10.22092/ari.2021.355581.1700. eCollection 2021 Nov. Arch Razi Inst. 2021. PMID: 35355759 Free PMC article.
-
Predictive Factors for Recovery Time in Conceived Women Suffering From Moderate to Severe Ovarian Hyperstimulation Syndrome.Front Endocrinol (Lausanne). 2022 Jun 15;13:870008. doi: 10.3389/fendo.2022.870008. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35784536 Free PMC article.
-
Dose Nomogram of Individualization of the Initial Follicle-Stimulating Hormone Dosage for Patients with Polycystic Ovary Syndrome Undergoing IVF/ICSI with the GnRH-Ant Protocol: A Retrospective Cohort Study.Adv Ther. 2023 Sep;40(9):3971-3985. doi: 10.1007/s12325-023-02582-2. Epub 2023 Jul 3. Adv Ther. 2023. PMID: 37395872 Free PMC article.
References
-
- Forman RG, Frydman R, Egan D, Ross C, Barlow DH. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil Steril. 1990;53:502–509. - PubMed
-
- Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58:249–261. - PubMed
-
- Delvigne A, Dubois M, Battheu B, Bassil S, Meuleman C, Sutter P, et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. Hum Reprod. 1993;8:1361–1366. - PubMed
-
- Schenker JG. Prevention and treatment of ovarian hyperstimulation. Hum Reprod. 1993;8:653–659. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources